Open Access Repository
Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome
Download Statistics
Downloads
Downloads per month over past year
Ding, C 2006
, 'Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome'
, Current Opinion in Investigational Drugs, vol. 7, no. 11
, pp. 1020-1025
.
|
PDF
vx-702.pdf | Download (221kB) Available under University of Tasmania Standard License. | Preview |
Official URL: http://www.biomedcentral.com/1472-4472/7?issue=11
Abstract
Vertex Pharmaceuticals Inc, in collaboration with Kissei
Pharmaceutical Co Ltd, is developing VX-702, one of a series of second-generation, orally active p38 MAP kinase inhibitors, for the potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases. In June 2005, a phase II clinical trial of VX-702 was initiated in rheumatoid arthritis. In July 2006, Vertex was planning to file an IND in the second half of 2006.
Item Type: | Article |
---|---|
Authors/Creators: | Ding, C |
Journal or Publication Title: | Current Opinion in Investigational Drugs |
ISSN: | 1472-4472 |
Additional Information: | restricted - published by Thompson |
Item Statistics: | View statistics for this item |
Actions (login required)
![]() |
Item Control Page |